However, a recent study shows that PRODH induced triple-negative breast cancer (TNBC) cell malignant phenotypes and overexpression of PRODH sensitized TNBC cells to clinical therapeutic drugs, including lipodox and Palbociclib [26]. The gene discussed is PRODH; the disease is triple-negative breast carcinoma.